Introduction
Dare Bioscience (DARE) is an interesting small biotech company, which develops new treatment methods for large markets, such as bacterial vaginosis, hormone-free contraceptive, and Female Sexual Arousal Disorder. However, despite the large potential market, it is still crucial to understand whether developed drugs are unique and could be able to compete in the marketplace. DARE-BV1 is the most developed drug of the company, which also received both Fast Track and Qualified Infectious Disease Product designations. Therefore, we wanted to investigate whether the upcoming pivotal Phase 3 results would be able to lift